List of Excipients in Branded Drug CLADRIBINE

« Back to Dashboard

Generic Drugs Containing CLADRIBINE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	cladribine	0143-9871	PHOSPHORIC ACID
Hikma Pharmaceuticals USA Inc	cladribine	0143-9871	SODIUM CHLORIDE
Hikma Pharmaceuticals USA Inc	cladribine	0143-9871	SODIUM PHOSPHATE, DIBASIC
Sandoz Inc	cladribine	0781-8201	HYDROXYPROPYL BETADEX
Sandoz Inc	cladribine	0781-8201	MAGNESIUM STEARATE
Sandoz Inc	cladribine	0781-8201	SORBITOL

What are the Most Frequently-Used Excipients in CLADRIBINE?

# Of NDCs	Excipient
3	HYDROXYPROPYL BETADEX
3	MAGNESIUM STEARATE
4	PHOSPHORIC ACID
4	SODIUM CHLORIDE
1	SODIUM PHOSPHATE DIBASIC DIHYDRATE
3	SODIUM PHOSPHATE, DIBASIC

Cladribine Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Cladribine has two commercially relevant formulation platforms: low-dose oral tablets for multiple sclerosis and dilute parenteral solutions for hematologic malignancies. The oral platform offers the stronger excipient opportunity because it combines a potent active ingredient, a short annual dosing schedule, strict handling requirements, and meaningful differentiation potential in stability, manufacturability, packaging, and patient use.

Mavenclad, Merck KGaA’s oral cladribine product, contains 10 mg cladribine per tablet and uses hydroxypropyl betadex, sorbitol, magnesium stearate, hypromellose, talc, titanium dioxide, and iron oxides as inactive ingredients. FDA approved Mavenclad in 2019 for adults with relapsing forms of multiple sclerosis, including relapsing-remitting disease and active secondary progressive disease. Injectable cladribine products, including Leustatin and Litak, use simpler sodium-chloride-based aqueous formulations.[1-4]

What excipients are used in approved cladribine products?

The approved products use different excipient strategies according to route, dose, and clinical setting.

Product	Route	Strength	Principal excipient strategy	Primary market
Mavenclad	Oral tablet	10 mg	Cyclodextrin-assisted solid dosage form with sorbitol and conventional tablet excipients	Multiple sclerosis
Leustatin	Intravenous solution	1 mg/mL	Sodium chloride, hydrochloric acid, and water for injection	Hairy cell leukemia
Litak	Subcutaneous solution	10 mg/mL in some markets	Sodium chloride, hydrochloric acid, and water for injection	Hairy cell leukemia

Mavenclad’s hydroxypropyl betadex is the key formulation excipient. Hydroxypropyl betadex, also known as hydroxypropyl-beta-cyclodextrin, can improve apparent solubility and support content uniformity for a low-dose active pharmaceutical ingredient. Sorbitol contributes to tablet bulk and may affect compressibility, hygroscopicity, and dissolution. Magnesium stearate supports lubrication but requires control because excessive blending can reduce tablet wettability and dissolution.

The parenteral products have limited excipient complexity. Their commercial value is concentrated in aseptic manufacturing, container-closure systems, extractables and leachables control, sterility assurance, and supply reliability rather than in novel excipient selection.[1,3,4]

How does cladribine’s physicochemical profile shape excipient selection?

Cladribine is a purine nucleoside analog with high pharmacologic potency. The oral product therefore requires a relatively small drug load. The main formulation issues are likely to be solid-state behavior, uniform distribution, dissolution, moisture exposure, and chemical stability rather than tablet mass.

A practical excipient program should address five technical risks.

Solubility and wetting

Cyclodextrin selection is central to the current oral formulation. Hydroxypropyl betadex can improve wetting and apparent solubility without requiring a large tablet. Alternative cyclodextrins, including sulfobutylether-beta-cyclodextrin, may offer different solubility, moisture, and compatibility profiles, but they would require comparative safety and performance justification.

Surfactants may improve wetting but can create risks involving taste, gastrointestinal tolerance, polymorphic conversion, and accelerated degradation. They are more attractive for a liquid or dispersible product than for a conventional swallowed tablet.

Low-dose content uniformity

At a 10 mg strength, segregation and over-lubrication must be managed carefully. Particle-size matching, ordered mixing, granulation, or a carrier-based premix may provide stronger control than simply increasing excipient quantity. Co-processed excipients could create a commercial niche if they improve blend uniformity while reducing manufacturing steps.

Moisture management

Sorbitol and cyclodextrins can affect water uptake. Moisture may change tablet hardness, dissolution, impurity growth, and packaging requirements. A development program should evaluate:

• Water activity and equilibrium moisture
• Tablet hardness after storage
• Disintegration and dissolution under humidity stress
• Hydrolysis or oxidation pathways
• Compatibility with desiccants and high-barrier blister systems

Alu-Alu blister packaging, high-barrier cold-form foil, or tightly controlled HDPE systems may be commercially relevant where stability data justify the added cost.

Lubrication and dissolution

Magnesium stearate is effective at low concentrations but can form hydrophobic films during extended blending. A generic developer should establish a design space for lubricant concentration and blending time. Alternatives such as sodium stearyl fumarate may improve dissolution in some tablet systems, although they can alter compaction, ejection force, and stability.

Taste and handling

Mavenclad tablets are swallowed whole. Taste masking is not a central requirement for the approved product, but it becomes important for pediatric, geriatric, dysphagia, or dispersible-product opportunities. Film coating can reduce handling exposure and improve identification. A dispersible or orally disintegrating product would require new work on taste, dose uniformity, particle suspension, and bioequivalence.

What formulation opportunities exist for generic and differentiated cladribine products?

The strongest commercial opportunity is an oral generic that matches Mavenclad’s route, strength, dosage form, and performance while reducing excipient complexity or manufacturing cost.

Generic 10 mg tablets

A standard immediate-release 10 mg tablet is the most direct opportunity. Developers can pursue:

1. A formulation closely matching the reference product.
2. A non-infringing formulation using a different solubilizer or binder.
3. A lower-cost formulation that removes or reduces cyclodextrin if dissolution and exposure remain acceptable.
4. A formulation optimized for direct compression or continuous manufacturing.

The commercial challenge is that cladribine is administered in short annual courses rather than continuously. Annual patient volume and payer access matter more than daily prescription volume. A generic may need a lower unit price, dependable supply, and specialty-pharmacy contracting to gain share.

Modified oral dosage forms

Potential differentiated products include:

• Orally disintegrating tablets
• Dispersible tablets
• Smaller tablets with higher drug concentration
• Unit-dose blister packs organized by treatment cycle
• Packaging with calendarized dosing instructions
• Pediatric or dysphagia-oriented liquid or multiparticulate systems

The clinical and regulatory burden rises as the dosage form departs from the reference product. A modified formulation may require comparative pharmacokinetic data, food-effect evaluation, dissolution bridging, and potentially clinical efficacy support.

Longer-stability or simplified parenteral products

The injectable market offers narrower formulation opportunities. Commercial improvements could include:

• Ready-to-use dilute infusions
• Lower-overfill presentations
• Improved container-closure compatibility
• Reduced adsorption to infusion materials
• Premeasured pharmacy-compounding formats
• Stabilized presentations with longer refrigerated or room-temperature storage

The main barriers are sterile manufacturing, low-volume specialty demand, and competition from established hospital products.

How strong is the commercial opportunity for excipient suppliers?

Excipient suppliers have four realistic entry points.

Opportunity	Customer need	Commercial attractiveness
Hydroxypropyl betadex supply	Reliable pharmaceutical-grade cyclodextrin for oral tablets	High
Co-processed low-dose tablet excipient	Better content uniformity and direct compression	Medium-high
Moisture-control platform	Stability improvement and lower packaging cost	Medium
Taste-masking or dispersible system	Differentiated oral dosage forms	Medium, but development-intensive
Parenteral compatibility materials	Container, tubing, and leachables control	Medium
Ready-to-use injectable platform	Reduced hospital preparation burden	Selective

The highest-value opportunity is not necessarily a novel excipient. A qualified, dual-sourced hydroxypropyl betadex grade with consistent impurity, particle-size, microbial, and residual-solvent profiles may have greater commercial value than a new excipient that triggers additional regulatory review.

Excipients that reduce the number of unit operations may also command interest. For example, a directly compressible carrier system that maintains dose uniformity at a 10 mg drug load could reduce granulation, drying, and in-process testing. The value proposition should be demonstrated through total cost of manufacture, not only tablet performance.

When does cladribine lose exclusivity and what generic entry risks exist?

Cladribine’s underlying compound is old, and injectable cladribine products have been marketed for decades. The principal protection risk for oral multiple-sclerosis products is therefore likely to arise from formulation, dosing regimen, method-of-use, and regulatory exclusivity rather than basic compound protection.

Mavenclad received FDA approval on March 29, 2019. FDA granted a seven-year orphan-drug exclusivity period for the approved multiple-sclerosis indication, subject to the scope of the orphan designation. That exclusivity period would generally extend into 2026, although the practical effect depends on the designated indication and the timing of any competing application.[1]

Patent expiration must be assessed separately from regulatory exclusivity. FDA’s Orange Book identifies patents and use codes submitted for approved drug products. The relevant analysis should distinguish:

• Compound patents
• Formulation patents
• Treatment-regimen patents
• Method-of-use patents
• Packaging or device claims
• Pediatric or other regulatory exclusivity

An ANDA applicant may file a Paragraph IV certification against listed patents. A patent-holder lawsuit filed within the statutory period can trigger a 30-month stay of approval, subject to statutory exceptions and litigation outcomes. Because Orange Book listings and patent terms can change, the live FDA Orange Book record and current USPTO data control the filing analysis.[5,6]

What is the Orange Book status of Mavenclad and how do Paragraph IV challenges matter?

Mavenclad is an FDA-approved small-molecule product listed in the Orange Book. It is not a biologic and therefore does not face biosimilar competition under the Biologics Price Competition and Innovation Act. Competition would arise through ANDAs, authorized generics, or potentially 505(b)(2) applications.

A generic applicant’s risk profile depends on whether the reference product has active listed patents and whether the proposed label includes the patented use. A carve-out may be possible for protected method-of-use claims, but the commercial value of a carve-out depends on whether the remaining label supports broad prescribing.

The most important patent questions are:

Question	Commercial implication
Are formulation patents listed?	Direct relevance to tablet composition and manufacturing route
Are regimen patents listed?	Potential restrictions on the annual two-course dosing schedule
Are use codes narrow or broad?	Determines whether a skinny label is practical
Is orphan exclusivity still active?	Can block approval even without blocking patents
Are settlements disclosed?	May establish an agreed generic launch date
Are patents challenged in litigation?	Determines the timing and cost of entry

Publicly available patent and litigation records should be reconciled before a development program commits to a formulation design. A composition that falls outside an Orange Book claim can still face non-listed patent risk, including process, polymorph, crystalline-form, or non-Orange-Book method patents.

What patent and manufacturing barriers affect cladribine excipient products?

Excipient suppliers face a different IP profile from generic drug manufacturers. A supplier may avoid the reference product’s composition claims while still creating value through:

• Particle-engineered hydroxypropyl betadex
• Co-processed excipient systems
• Moisture-resistant granules
• Low-shear premixes for low-dose APIs
• Packaging and desiccant combinations
• Continuous-manufacturing processes
• Stability-indicating manufacturing controls

Freedom-to-operate analysis should cover both composition and process claims. A new excipient grade may itself be patentable if it has a defined substitution profile, particle-size distribution, moisture specification, or performance advantage. Regulatory acceptance remains essential because an excipient with limited pharmaceutical precedent may increase review complexity.

Manufacturing barriers are more significant for injectable cladribine. Sterility, endotoxin, particulate matter, container compatibility, and validated aseptic filling can prevent rapid market entry even when the formulation is chemically simple.

How does cladribine compare with other multiple-sclerosis oral drugs?

Cladribine has a different commercial and excipient profile from daily oral multiple-sclerosis therapies.

Product class	Dosing pattern	Excipient opportunity	Competitive issue
Cladribine tablets	Short annual courses	High value in stability, packaging, dose uniformity, and cycle-based presentation	Low cumulative tablet volume but high specialty value
Dimethyl fumarate	Chronic oral dosing	Strong opportunity in delayed release and gastrointestinal tolerability	Mature generic competition
Teriflunomide	Daily oral dosing	Conventional tablet and film-coating opportunities	Broad generic pressure
Fingolimod	Daily oral dosing	Capsule/tablet bioequivalence and stability	Generic and regulatory complexity
Siponimod	Daily oral dosing	Dose-ranging and solid-state control	More complex pharmacogenetic and titration requirements

Cladribine’s short-course regimen reduces tablet consumption but increases the importance of packaging, adherence control, and specialty distribution. A supplier that solves treatment-cycle packaging or reduces manufacturing cost may capture more value than one offering a marginal change in tablet disintegration.

What FDA regulatory pathway applies to cladribine formulations?

For a conventional generic Mavenclad tablet, the principal pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence and comply with current good manufacturing practice requirements.[7]

A 505(b)(2) application may be more appropriate for:

• A new dosage form
• A new route
• A modified-release formulation
• A dispersible or orally disintegrating product
• A new strength or presentation not adequately covered by the reference product

The FDA Inactive Ingredient Database can support excipient precedent assessment, but database presence does not eliminate the need to evaluate route, maximum daily exposure, dosage form, and patient population.[8]

What is the best commercial strategy for cladribine excipients?

The most defensible strategy is a platform built around pharmaceutical-grade hydroxypropyl betadex, low-dose blend uniformity, and moisture-controlled packaging. The supplier should target both generic manufacturers and contract development and manufacturing organizations working on oral cladribine products.

A second-tier opportunity is a dispersible or orally disintegrating product designed for patients who cannot swallow conventional tablets. That opportunity is technically attractive but carries greater clinical, regulatory, and intellectual-property risk.

The injectable market is best approached through manufacturing partnerships rather than standalone excipient sales. Ready-to-use presentations, container-closure systems, and sterile filling services may produce more value than a new aqueous excipient system.

Key Takeaways

• Mavenclad is the primary commercial target for oral cladribine excipient innovation.
• Hydroxypropyl betadex is the central excipient in the approved oral formulation.
• The highest-value technical problems are low-dose content uniformity, moisture control, dissolution, and cycle-based packaging.
• A conventional 10 mg generic tablet is the most accessible entry route.
• Orally disintegrating, dispersible, and calendarized products offer differentiation but increase regulatory and IP risk.
• Cladribine is a small molecule, so generic competition occurs through ANDAs rather than biosimilars.
• FDA orphan exclusivity for the multiple-sclerosis indication was granted in connection with the 2019 Mavenclad approval and extends into the mid-2020s, subject to the scope of the designation.
• Current Orange Book listings, patent terms, use codes, and litigation records must determine Paragraph IV and launch strategy.
• Injectable cladribine offers fewer excipient innovations but meaningful opportunities in ready-to-use presentation, sterility assurance, and container compatibility.
• A reliable pharmaceutical-grade hydroxypropyl betadex supply chain may be commercially more valuable than an entirely new excipient.

FAQs About Cladribine Excipient and Generic Opportunities

Can hydroxypropyl betadex be replaced in a generic cladribine tablet?

Yes. A generic applicant may use a different excipient composition if the product meets pharmaceutical-equivalence, bioequivalence, quality, stability, and performance requirements. The replacement must also avoid relevant formulation claims.

Is cladribine a biologic requiring biosimilar competition?

No. Cladribine is a synthetic small-molecule purine nucleoside analog. Regulatory competition is generally through ANDAs or, for materially different products, 505(b)(2) applications.

What is the most attractive differentiated cladribine dosage form?

A dispersible or orally disintegrating tablet is the clearest differentiated concept, particularly for swallowing difficulty. It requires careful control of taste, dose uniformity, dissolution, moisture, and comparative exposure.

Does a low tablet count reduce the value of cladribine excipient innovation?

It limits total volume but increases the value of reliable manufacturing, packaging, and specialty distribution. The commercial case depends on market access and supply contracts, not tablet count alone.

Are cladribine formulation patents necessarily listed in the Orange Book?

No. Only patents submitted for listing and accepted under FDA requirements appear in the Orange Book. Non-listed formulation, process, polymorph, and method patents may still create litigation or freedom-to-operate risk.

References

1. U.S. Food and Drug Administration. (2019). Mavenclad (cladribine) tablets prescribing information.
2. Merck KGaA. (2024). Mavenclad product information. European Medicines Agency.
3. DailyMed. (n.d.). Leustatin (cladribine) injection prescribing information. U.S. National Library of Medicine.
4. European Medicines Agency. (n.d.). Litak: EPAR product information.
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
6. United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term information resources.
7. U.S. Food and Drug Administration. (2013). ANDA submissions: Refuse-to-receive standards.
8. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database.